Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

GBD 2016 Multiple Sclerosis Collaborators. · 2019

Read Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. by GBD 2016 Multiple Sclerosis Collaborators. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6372756.txt.

Introduction

The GBD 2016 Multiple Sclerosis Collaborators present a systematic analysis in The Lancet Neurology. The study estimates the global burden of multiple sclerosis from 1990 to 2016. It models prevalence, deaths, and disability for every region, and relates burden to a country's development level.

In 2016 the team counted about 2.22 million people living with multiple sclerosis worldwide. Age-standardised prevalence had risen 10.4 percent since 1990. Rates were highest in high-income North America and western Europe, and lowest in sub-Saharan Africa and Oceania. The disease caused 18,932 deaths and about 1.15 million disability-adjusted life-years. The authors note large data gaps in many regions.

Catalog record

CREATORGBD 2016 Multiple Sclerosis Collaborators.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6372756

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Published in: The Lancet. Neurology DOI: 10.1016/S1474-4422(18)30443-5 ABSTRACT Summary Background Multiple sclerosis is the most common inflammatory neurological disease in young adults. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic method of quantifying various effects of a given condition by demographic variables and geography. In this systematic analysis, we quantified the global burden of multiple sclerosis and its relationship with country development level. Methods We assessed the epidemiology of multiple sclerosis from 1990 to 2016. Epidemiological outcomes for multiple sclerosis were modelled with DisMod-MR version 2.1, a Bayesian meta-regression framework widely used in GBD epidemiological modelling. Assessment of multiple sclerosis as the cause of death was based on 13 110 site-years of vital registration data analysed in the GBD's cause of death ensemble modelling module, which is designed to choose the optimum combination of mathematical models and predictive covariates based on out-of-sample predictive validity testing. Data on prevalence and deaths are summarised in the indicator, disability-adjusted life-years (DALYs), which was calculated as the sum of years of life lost (YLLs) and years of life lived with a disability. We used the Socio-demographic Index, a composite indicator of income per person, years of education, and fertility, to assess relations with development level. Findings In 2016, there were 2 221 188 prevalent cases of multiple sclerosis (95% uncertainty interval [UI] 2 033 866–2 436 858) globally, which corresponded to a 10·4% (9·1 to 11·8) increase in the age-standardised prevalence since 1990. The highest age-standardised multiple sclerosis prevalence estimates per 100 000 population were in high-income North America (164·6, 95% UI, 153·2 to 177·1), western Europe (127·0, 115·4 to 139·6), and Australasia (91·1, 81·5 to 101·7), and the lowest were in eastern sub-Saharan Africa (3·3, 2·9–3·8), central sub-Saharan African (2·8, 2·4 to 3·1), and Oceania (2·0, 1·71 to 2·29). There were 18 932 deaths due to multiple sclerosis (95% UI 16 577 to 21 033) and 1 151 478 DALYs (968 605 to 1 345 776) due to multiple sclerosis in 2016. Globally, age-standardised death rates decreased significantly (change −11·5%, 95% UI −35·4 to −4·7), whereas the change in age-standardised DALYs was not significant (−4·2%, −16·4 to 0·8). YLLs due to premature death were greatest in the sixth decade of life (22·05, 95% UI 19·08 to 25·34). Changes in age-standardised DALYs assessed with the Socio-demographic Index between 1990 and 2016 were variable. Interpretation Multiple sclerosis is not common but is a potentially severe cause of neurological disability throughout adult life. Prevalence has increased substantially in many regions since 1990. These findings will be useful for resource allocation and planning in health services. Many regions worldwide have few or no epidemiological data on multiple sclerosis, and more studies are needed to make more accurate estimates. Funding Bill & Melinda Gates Foundation. INTRODUCTION Multiple sclerosis is the most common inflammatory neurological disease in young adults. The mean age of diagnosis is approximately 30 years, with most patients presenting with periodic neurological relapses.1 One to two decades after onset, many patients with multiple sclerosis enter a progressive phase of the disease. Several environmental factors and genetic alleles might alter the risk of developing multiple sclerosis, but the underlying cause of the disease remains elusive.2, 3 Common neurological manifestations of multiple sclerosis include optic neuritis, diplopia, sensory loss, limb weakness, gait ataxia, loss of bladder control, and cognitive dysfunction. 15 medications have been approved by the US Food and Drug Administration to reduce the number of relapses and attenuate progression of neurological disability.1 These drugs are partly effective, but whether they alter the long-term course of multiple sclerosis remains unclear.4 The epidemiology of multiple sclerosis has been the subject of many studies. Over the past five decades, prevalence has been rising across North America and Europe, high incidence has been seen among women and among African Americans, and persistent geographical risk gradients have been documented.5, 6, 7, 8, 9 Contemporary reviews have provided updates on the prevalence, incidence, and burden of multiple sclerosis in the Americas,5 Europe,6 and worldwide.7 The MS International Federation has compiled a useful international atlas of the epidemiology of multiple sclerosis with detailed country-level data, but this group did not use systematic modelling for disease morbidity, mortality, and risk factors.10 The lack of standardisation in the methods of epidemiological studies limits comparisons of findings and assessments of multiple sclerosis with those of other conditions. Additionally, few evaluations have been done at the country level, epidemiological data in different ethnic groups are incomplete, and many regions of the world remain to be studied. Research in contextEvidence before this studyWe searched PubMed for studies published between 2011 and 2015 that were representative, population-based surveys, including retrospective case-report and hospital-report analyses and nationally representative health studies. The search string used was “multiple sclerosis AND epidemiology AND (2011/01/01: 2015/12/31)”. Additional searches for features such as prevalence, disability-adjusted life-years, years of life lost, and mortality are reviewed in the appendix. Global estimates of prevalence, incidence, and deaths from multiple sclerosis have been made in past iterations of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD). Other epidemiological studies have focused on variations in prevalence and incidence of multiple sclerosis between individual countries and noted marked differences along latitude gradients. Similar data have been recorded on a map produced by the MS International Federation. The GBD study uses an integrated modelling approach to predict morbidity and mortality in countries and regions of the world from where there are insufficient data. Previously, estimates for multiple sclerosis have been summarised in GBD reports about other diseases, but no report has focused exclusively on this disease.Added value of this studyThis Article presents the methods and results for a focused GBD 2016 analysis of multiple sclerosis, making use of detailed country-level morbidity and mortality data. We have explored variation in the burden of multiple sclerosis by country development level, as measured by the Socio-demographic Index, which is a composite indicator of income per person, years of education, and fertility.Implications of all the available evidenceMultiple sclerosis is quite rare but is a potentially severe cause of neurological disability. Onset is typically in young adulthood, after which symptoms persist throughout adult life. Prevalence has increased in many world regions, due in part to improved survival. These findings are relevant to researchers, clinicians, and health policy makers. The health service needs of the increasing number of patients with multiple sclerosis must be considered. Several disease-modifying therapies have been developed that reduce the number of relapses and slow neurological disability, at least during the early phases of the disease. Although expensive, these medications are important components of comprehensive multiple sclerosis care, along with rehabilitation and access to multidisciplinary care. More national, epidemiological studies in multiple sclerosis are needed for GBD to generate more robust worldwide estimates in the future. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic method of quantifying health loss in great detail for a given condition by demographic variables and geographical location.11 By using information from the literature, population statistics, and rigorous algorithms, a consistent picture is produced across

Read the complete text